Pharmaceutical Project Management – Getting Back to Basics

3rd /4th November 2015 - Ipsen, Paris, France

Kindly hosted by: Ipsen
Innovation, 5 Ave du Canada, 91140 Ulis (Les), Paris, France

www.pipmg.org
info@pipmg.org

Book Now!
Background

Key objectives of this PIPMG meeting are to encourage attendees to focus on getting back to basics with project management. Experienced pharmaceutical industry professionals will share their experiences and perspectives including:

- How to simplify projects, save time and energy while still doing the essentials needed to help ensure project success
- Key ‘tools’ needed in the Project Manager’s Toolbox

Aim is to cover all key stages of the project lifecycle (Initiating, Planning and forecasting, Executing, Monitoring and Controlling, Closing) and to examine tools that can help your company determine its location on its journey towards project and portfolio management excellence.
12:30  Registration & Coffee

13:00  Welcome & Introduction  
Mary Charteris, Steven Harrison, Tom Halliwell from PIPMG

13:15  Initiating Projects Successfully  
Romuald Lainé, Director and Global Project Leader, Ipsen  
- The importance of successfully initiating a project  
- Steps required to successfully initiate a project  
- Defining roles, responsibilities and expectations  
- Identifying and managing stakeholders expectations  
- The project charter

14:00  Optimal Planning & Forecasting of Projects  
Janette Thomas, Director, AccentBio Ltd, UK  
- Steps required for optimal planning and forecasting of projects  
- Approaches to project planning  
- Methods of estimating and forecasting projects

14:45  Workshop1 – Project Start-up

15:45  Break

16:15  Successfully Executing Projects  
Hélène Pelletier, Project Management, GSK  
- Key factors required for successful project execution  
- Coordinating people and resources  
- Performing project activities in accordance with the project plan  
- Ownership of deliverables

17:00  Summary & Networking

18:00  Meeting Close

19:00  Drinks Reception  19:30  Dinner

Hotel Mercure, Les Ulis

21:30  After dinner speaker – Claude Bertrand, Executive VP of R&D, Ipsen. Why being project-centric is so good for Pharmaceutical companies
08:30  Registration & Coffee

09:00  Welcome & Next PIPMG Meeting
   Mary Charteris, Steven Harrison, Tom Halliwell from PIPMG

09:15  Suitability for and survival as a project manager
   John Faulkes, PPMLD
   • The key flaw in matrix management
   • The 'ideal' PM personality – and how can it be developed?
   • Tools and tips to overcome common problems as a PM
   • Raising the commitment and efficiency of an (almost) willing team

10:00  Workshop 2 – Project Execution - Monitoring and Controlling Projects

11:00  Break

11:30  Closing Projects
   Tim Harris, Director, Turnstone Business Solutions Ltd, UK
   • Preparing the close out plan
   • Finishing well
   • Capturing lessons learnt

12:15  Lunch

13:30  Workshop 3 – Project Closure and Lessons Learned

15:00  Break

15:20  From Project Management to Programme Leadership – assessing maturity and developing capability
   Mark Abbott, Senior Manager Strategy & Operations, Deloitte
   • What is the value of project management
   • How to move up the project management maturity ladder
   • Assessing and developing capability

16:05  Panel Discussion & Summary

16:30  Wrap up and Meeting Close
Romuald Lainé, Director Global Project Leader, Ipsen
Romuald has a PhD in molecular and Cellular Biology. He has led early and late stage development projects, submitting NMEs in the US and EU leading to approval. Currently he is responsible for various registration projects in the EU and China.

After a PostDoctoral Fellowship in the University of California San Francisco, Romuald started his Career in the academic area as assistance professor at Pierre et Marie Curie university (Paris 6). He then joined Laboratoires Fournier as Head of Drug metabolism followed by an Associate Director position in DMPK at AstraZeneca, having a project leader role as well.

His career in the project management was pursued at Pfizer and Guerbet. Romuald joined ISPEN in 2012.

Dr Janette Thomas – Director, AccentBio Ltd
Janette is an experienced senior executive in project management and operations with 25 years’ experience in the pharmaceutical and biotechnology industry. She has led R&D and international pharmaceutical drug development projects for GSK, CELS, Gardant, Jomaa Pharma, Immodulon, and Horizon Discovery.

She is currently working with Atlantic Pharmaceuticals Ltd on a Phase 3 project for Inflammatory Bowel Disease, Integrated Medicines Ltd on a care pathway model for Sepsis, and Healx Ltd, repurposing drugs for rare diseases.

Hélène Pelletier, Project Management, GSK
Helene obtained a PhD degree in biology from the Burgundy University (Dijon, France) in 1988 and pursued a post-doc in the same INSERM Unit during 2 years for Glaxo before to join the pool of biology researchers of the French Research Center in Paris (Les Ulis).

As researcher, she led several Drug Discovery projects in immuno-oncology and cardiovascular areas. One founder experience has been to lead during 2 years an international team (clinicians, regulators, production) to reposition a Multi Drug Resistance inhibitor for treatment of breast cancer (US Phase I/II clinical trials). Helene moved to a permanent Project Manager position in 1998 and since has developed a deep knowledge of early phases of pharmaceutical development and the ability to manage international and multi-functional groups in diverse contexts and a wide variety of therapeutic areas (immunology, oncology, cardiovascular, metabolic, neurosciences, respiratory, dermatology).

Since 3 years, Helene is part of a new and innovative GSK group developing a portfolio of Drug Discovery projects in collaboration with academic labs/institutions in Europe and North America. This experience is reinforcing the skills required to provide Project and Portfolio Management support to multi-located and multi-cultural teams.
John Faulkes, PPMLD
John has worked for 20 years as a consultant focusing on leadership, project team effectiveness, change management and partnership working. He began his career as a scientist in a diagnostics company, and still works for many lifescience clients, big pharma, small biotech and public sector.

In the last 5 years John has focused particularly on relationship building and relationship skills development, developing clients’ alliance management and CRO outsourcing capabilities. He has published articles, particularly around overcoming problems in CRO outsourcing, in the Journal of Clinical Studies and other publications. He has spoken and led workshops at Partnerships in Clinical Trials, the DIA annual meetings and One Nucleus forums.

John is on the Exec committee of the Pharmaceutical Industry Project Management Group (PIPMG), and helps to organise regular networking meetings in the UK and mainland Europe. He is also a founder member of a new association, The Collaboration Project, which seeks to build an open network for alliance managers, outsourcing managers, project managers and others involved in partnership working.

Dr Tim Harris, Turnstone Business solutions
Independent Consultant and former Portfolio Director, GlaxoSmithKline R&D.

Tim has nearly 30 years’ experience in the pharmaceutical industry with roles in clinical research, project management, portfolio management and R&D strategy. After coordinating the UK commercial introduction of a number of blockbusters Tim defined a global project budgeting process, managed a European Business Team and spent 5 years in R&D Strategy supporting the R&D Executive Committees of GSK before leading Portfolio Management for the Respiratory franchise. He also ran a major change initiative in Emerging Markets and Asia Pacific Regulatory Affairs before starting an independent consultancy.

Tim has a BA in Biology and a DPhil in cardiac structure and physiology both from the University of York.

Tim is on the Exec committee of the Pharmaceutical Industry Project Management Group (PIPMG), and helps to organise regular networking meetings in the UK and mainland Europe.
Mark Abbot, Senior Manager Strategy & Operations, Deloitte Consulting AG, Switzerland

Mark co-Leads Deloitte’s Programme Leadership capability in Switzerland. He has over 15 years consulting and industry experience in both shaping and managing complex transformative initiatives across life sciences, manufacturing and consumer business sectors. Mark is a specialist in portfolio assurance and turnaround of mishandled programmes.

His expertise covers the full lifecycle of programme design and implementation with a proven track record in bringing major programmes to fruition. He frequently works across borders and understands the cultural, geographic and political complexities that this can often present.

Mark is a British national resident in Switzerland, a Chartered Engineer by education, and originally developed his expertise as an R&D programme manager in the automotive industry. He tries to balance his Consulting career whilst being a semi-professional racing driver.
Tom Halliwell – Therapy Area Director, Norgine Ltd
Tom has over 30 years’ experience in the Pharmaceutical and Diagnostic industries and has worked on projects spanning all phases of development and a wide variety of therapy areas. Tom has been responsible for the development and launch of a number of diagnostic products as project leader (including Amerlite anti-HBs and HAV IgM) and a number of medicinal products as global project manager (including Herceptin, Avastin and Bondronat).

As a Therapy Area Director at Norgine, Tom has overall leadership and governance responsibility for a group of pipeline products and is a member of Norgine’s New Products Committee (senior management committee that has oversight of Norgine’s product pipeline and line extension portfolio).

Tom is a Fellow of the Institute of Biomedical Sciences and a member of the Association of MBA’s. Tom is also a member of the Pharmaceutical Industry Project Management Group’s Executive Committee and a former Chairman.

Mary Charteris – Research and Development Planning Manager, Ipsen Bioinnovation Ltd
Mary Charteris has 11 years of experience as a research laboratory scientist in both academic and biotech industries and 5 years running her own business in the leisure industry. Initially working in virology for Porton International and at the Centre for Applied Microbiology and Research, Porton Down and also in the USA (University of Washington, Seattle), Mary has since worked in the field of botulinum neurotoxins at the Health Protection Agency (now Public Health England) and more recently at Syntaxin Ltd. Since 2006 Mary held the position of Research Project Leader for a respiratory project and Development Project Planner for the early stage development of a new class of biological drug within Syntaxin’s proprietary technology platform of Targeted Secretion Inhibitors. Mary is now Research and Development Planning Manager at Ipsen Bioinnovation Ltd providing project management across the company’s project portfolio. In addition, Mary is an IOSH Chartered Practitioner of Safety and Health and also holds the role of Environment, Health and Safety Manager at Ipsen Bioinnovation Ltd.

Steven Harrison, Project manager, Immodulon
Originally trained as a microbiologist, Steven has worked in the bio-pharmaceutical industry, for over 20 years. He has managed multi-disciplinary projects, developing both small molecules and complex biologics, across several therapeutic areas, including cancer, allergic disorders and pain.

Working with some of the UK’s foremost biotech companies, including Immodulon Therapeutics, Glide Technologies, Sosei R & D Ltd., and SR Pharma, he also spent some time at the Centre of Molecular Immunology (CIM) in Cuba, for the Canadian company YM Biosciences Inc. Previously, seven years at the Health Protection Agency (Public Health England), presented the first opportunity to develop programme and line management skills, coordinating high performing teams across a diverse range of National health, and defence programmes.
Event prices
There are three packages available:

<table>
<thead>
<tr>
<th>Package</th>
<th>Price (ex VAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full package including both days of the meeting (3rd/4th November) and the Networking dinner on the evening of the 3rd</td>
<td>£450.00</td>
</tr>
<tr>
<td>Day 1 only</td>
<td>£200.00</td>
</tr>
<tr>
<td>Day 2 only</td>
<td>£350.00</td>
</tr>
</tbody>
</table>

Note
These packages do not include accommodation, which if required can be separately purchased. PIPMG will not book accommodation but offers suggestions locally – see over.
Some Local Hotels:
Mercure Les Ulis
Within walking distance of the site

Campanile Les Ulis
Within walking distance of the site

Mercure Paris Massy Gare TGV
Closest to station and morning bus to Ipsen

Novotel Massy Palaiseau
Longer walk to the station and morning bus to Ipsen

IBIS Massy
Nearest RER Les Baconnets, two stops to Massy and morning bus to Ipsen or taxi

Travel Suggestions:
Orly Airport
Taxi to Massy or Les Ulis ~ Euro 40
RER to Massy Palaiseau (1 change), bus or taxi to Les Ulis

CDG Airport
Taxi to Massy or Les Ulis ~Euro 75 - 90
Direct RER to Massy Palaiseau, bus or taxi to Ipsen

Eurostar from London, Brussels etc
Direct RER from Paris Gare Du Nord to Massy Palaiseau, bus or taxi to Les Ulis